In light of the above, we analyzed a series of well characterized archival invasive ductal carcinoma specimens in order to better understand which BCa subtypes are more likely to be driven by MYC with potential co-amplification of HER2. The objective of the study was to determine the prevalence...
MYC-driven pathways in breast cancer subtypes. Biomolecules. 2017;7:53. Article Google Scholar Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 2000;19:1647–56. Article CAS...
MYC-driven pathways in breast Cancer subtypes. Biomolecules. 2017;7(3). https://doi.org/10.3390/biom7030053. Article PubMed Central Google Scholar Gupta N, Jung K, Wu C, Alshareef A, Alqahtani H, Damaraju S, Mackey JR, Ghosh S, Sabri S, Abdulkarim BS, et al. High Myc expression...
Breast cancer is a complex and heterogeneous disease with distinct subtypes and molecular profiles corresponding to different clinical outcomes. Mouse models of breast cancer are widely used, but their relevance in capturing the heterogeneity of human disease is unclear. Previous studies have shown the ...
Breast cancer consists of highly heterogeneous tumors, whose cell of origin and driver oncogenes are difficult to be uniquely defined. Here we report that MYC acts as tumor reprogramming factor in mammary epithelial cells by inducing an alternative epige
While mutations in Kras and overexpression of Myc are commonly found in patients, the role of altered lipid metabolism in lung cancer and its interplay with oncogenic Myc is poorly understood. Here we use a transgenic mouse model of Kras-driven lung adenocarcinoma with reversible activation of Myc...
MYC, a major oncogenic transcription factor, regulates target genes involved in various pathways such as cell proliferation, metabolism and immune evasion, playing a critical role in the tumor initiation and development in multiple types of cancer. In liver cancer, MYC and its signaling pathways unde...
PP2A DT-061/(AZD6244) KRAS-driven lung cancer mouse models, lung adenocarcinoma xenografts, non-small cell lung cancer xenografts. Pre-clinical FTY720 leukemia, colon cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, prostate cancer. Pre-clinical OP449 AML, breast can...
is predictive of NELFE/MYC-driven tumors that would otherwise not be identified by gene amplification or translocation alone. We demonstrate the utility of the NDMT gene signature to predict a unique subtype of HCC, which is associated with a poor prognosis in three independent cohorts encompassing...
25,26Besides being a renowned master regulator of cell proliferation and survival pathways, MYC is also implicated in many resistance mechanisms to targeted therapies.27Consequently, the MYC pathway, along with MYC itself, has been regarded as a promising target for cancer therapy for several years...